~23 spots leftby Mar 2026

ABP-671 for Gout

Recruiting in Palo Alto (17 mi)
+57 other locations
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2 & 3
Waitlist Available
Sponsor: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
No Placebo Group
Prior Safety Data

Trial Summary

What is the purpose of this trial?The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participants with gout who roll over from Study ABP-671-301 after they complete the double-blind 28-week Treatment Period of Part 1 (Phase 2b) or Part 2 (Phase 3).

Eligibility Criteria

This trial is for people with gout who finished the initial 28-week treatment in Study ABP-671-301 and are doing well on the medication. They can't join if they have new health or mental issues, plan to get pregnant or breastfeed soon, or can't take colchicine or naproxen.

Exclusion Criteria

I cannot or do not want to take colchicine or naproxen.

Participant Groups

The study tests the safety and effectiveness of a drug called ABP-671 in lowering uric acid levels in gout patients. It's an extension of a previous study where participants continue with their current treatment from that study.
2Treatment groups
Experimental Treatment
Active Control
Group I: ABP-671Experimental Treatment1 Intervention
Group II: AllopurinolActive Control1 Intervention

Find A Clinic Near You

Research locations nearbySelect from list below to view details:
Access Research InstituteBrooksville, FL
DelRicht Research of GulfportGulfport, MS
Center for Clinical Trials of SacramentoSacramento, CA
Century Research LLCMiami, FL
More Trial Locations
Loading ...

Who is running the clinical trial?

Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.Lead Sponsor

References